Clinical Trials
276 trialsA Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
STELLAR-002
Exelixis
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Boehringer Ingelheim
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
AFAN
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
NEOS
Yonsei University
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
JADE
GlaxoSmithKline
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
University of Wisconsin, Madison
SCREEN-HPV
UNICANCER
eVOLVE-02
AstraZeneca
Effectiveness of Opioid vs Pregabalin Plus Naproxen Sodium in Pain Management of Oral Cancer Patients
Mayo Hospital Lahore
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NRG Oncology
ORCA-2
University College, London
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
University of Arizona
AHEAD-MERIT
BioNTech SE
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Wake Forest University Health Sciences
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
Indiana University
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
PIKALO-1
Eli Lilly and Company
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
INVOKE
Epkin
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
InduPro, Inc.
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Boehringer Ingelheim
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
H. Lee Moffitt Cancer Center and Research Institute
DESCENT-1
A2 Biotherapeutics Inc.
ILLUMINE
Groupe Oncologie Radiotherapie Tete et Cou
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
Medical University of South Carolina
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
3D Specimen Maps for RT Planning
Vanderbilt University Medical Center
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Lyvgen Biopharma Holdings Limited
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
AbbVie
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Merus B.V.
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono